类风湿关节炎中生物改善病情抗风湿药与Janus激酶抑制剂单药治疗的比较有效性
多中心队列研究纳入635例类风湿关节炎患者的849个治疗疗程,比较IL-6受体抑制剂、CTLA4Ig、JAK抑制剂与TNF抑制剂单药治疗。24周时IL-6受体抑制剂组DAS28-ESR下降幅度大于TNF抑制剂组,CTLA4Ig和JAK抑制剂组与TNF抑制剂组相似。IL-6受体抑制剂组总体停药风险显著低于TNF抑制剂组。
要点
- 24周时IL-6受体抑制剂单药治疗DAS28-ESR改善优于TNF抑制剂单药治疗。
- CTLA4Ig和JAK抑制剂单药治疗的DAS28-ESR改善与TNF抑制剂单药治疗相似。
- IL-6受体抑制剂单药治疗总体药物留存优于TNF抑制剂单药治疗。
核心结论
- 在采用逆概率加权减少选择偏倚的分析中,IL-6受体抑制剂单药治疗在有效性和药物留存方面优于TNF抑制剂单药治疗。
- CTLA4Ig、JAK抑制剂与TNF抑制剂单药治疗之间未发现显著差异。
研究设计与样本
- 多中心队列研究,纳入已启动bDMARD或JAK抑制剂单药治疗(未联用传统合成DMARD)的类风湿关节炎患者。
- 单药方案分为IL-6受体抑制剂、CTLA4Ig、JAK抑制剂和TNF抑制剂四组。
- 采用多重倾向性评分逆概率加权减少选择偏倚,以线性混合效应模型分析24周DAS28-ESR变化,以逆概率加权Cox比例风险模型比较药物留存。
主要发现
- 共纳入849个治疗疗程,涉及635例患者:IL-6受体抑制剂218个、CTLA4Ig 183个、JAK抑制剂92个、TNF抑制剂356个。
- 主要结局24周DAS28-ESR变化:IL-6受体抑制剂组较TNF抑制剂组低0.93(95%CI:-1.20至-0.66)。
- CTLA4Ig组与JAK抑制剂组24周DAS28-ESR变化与TNF抑制剂组相似,分别为-0.20(95%CI:-0.48至0.08)和-0.25(95%CI:-0.67至0.16)。
- IL-6受体抑制剂组总体药物停药风险显著低于TNF抑制剂组,风险比=0.55(95%CI:0.39-0.78),P=0.001。
- CTLA4Ig组和JAK抑制剂组的药物留存率与TNF抑制剂组相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to examine the effectiveness and drug tolerability of biological DMARD (bDMARD) and Janus kinase inhibitor (JAKi) monotherapy in patients with RA in a multicentre cohort study. METHODS: Patients with RA for whom bDMARD/JAKi monotherapy without conventional synthetic DMARDs has been initiated were included. Monotherapy regimens were categorized as IL-6 receptor inhibitors (IL-6Ris), cytotoxic T-lymphocyte-associated protein 4 immunoglobulin (CTLA4Ig), JAKis, or TNF inhibitors (TNFis). Multiple propensity score-based inverse probability weighting (IPW) was used to reduce selection bias. Linear mixed-effect models with IPW were used to examine changes in the DAS in 28 joints using ESR (DAS28)-ESR at 24 weeks, and drug retention was compared between monotherapy groups using IPW Cox proportional hazards models. RESULTS: A total of 849 treatment courses were included, involving 635 patients (IL-6Ris, 218; CTLA4Ig, 183; JAKis, 92; TNFis, 356). The change in DAS28-ESR at week 24 as the primary outcome was -0.93 (95% CI: -1.20 to -0.66) lower in the IL-6Ri group than in the TNFi group, while those of the CTLA4Ig and JAKi groups were similar to that of the TNFi group [-0.20 (-0.48 to 0.08), -0.25 (-0.67 to 0.16), respectively]. IL-6Ri use was associated with significantly lower overall drug discontinuation than that for TNFi use [hazard ratio = 0.55 (0.39-0.78), P = 0.001]. Similar retention rates were identified for the CTLA4Ig and JAKi groups to that of the TNFi group. CONCLUSION: In the analysis with IPW to reduce selection bias, IL-6Ri monotherapy was superior to TNFi monotherapy in terms of effectiveness and drug retention. No significant differences were identified between CTLA4Ig, JAKi and TNFi monotherapy.
引用
- Onishi A, Yamada H, Yamamoto W, et al. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis. Rheumatology (Oxford). 2024. PMID: 37988163. doi:10.1093/rheumatology/kead620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。